Timing a Key Factor in DHAs Ability to Fight Alzheimers

April 23, 2010

1 Min Read
SupplySide Supplement Journal logo in a gray background | SupplySide Supplement Journal

LEXINGTON, Ky.The benefits of supplemental omega-3s in treating Alzheimers disease may depend on the stage of the disease, dietary mediators and apolipoprotein E status, according to a review in Clinical Interventions in Aging (2010 Apr 7;5:45-61). Researchers from the University of Kentucky, Lexington, noted omega-3s are essential for brain growth and development, and help modulate neuronal function. More research is underscoring the particular importance of docosahexaenoic acid (DHA) in the development of several neurological and psychiatric disorders, including Alzheimers disease; in particular, cross sectional and prospective cohort data suggest low dietary intake or low brain levels of DHA are connected to onset of dementia and accelerated cognitive decline. However, several clinical trials using supplemental DHA have not demonstrated efficacy in treating Alzheimers, which suggest the success of intervention may be dependent on other factors such as disease progression or other dietary factors.

Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.

You May Also Like